|
|||||
|
|
| 贝伐单抗联合FOLFOX4治疗晚期结直肠癌临床研究 | |
| 引用本文： | 谢剑明,谢亚琳,陈锦章,李黎波,廖旺军. 贝伐单抗联合FOLFOX4治疗晚期结直肠癌临床研究[J]. 中国热带医学, 2010, 10(11): 1393-1394 |
| 作者姓名： | 谢剑明 谢亚琳 陈锦章 李黎波 廖旺军 |
| 作者单位： | 南方医科大学南方医院,广东,广州,510515 |
| 摘 要： | 目的采用FOLFOX4及FOLFOX4加Avastin两种方案治疗转移性结直肠癌，观察两者的疗效。方法选择ECOG功能状态评分在0～2，128例转移性结直肠癌患者，随机分成A、B两组，分别采用FOLFOX4和FOLFOX4加Avastin方案治疗六个周期。结果A组有81例：完全缓解（CR）1．2％，部分缓解（PR）38．3％，总有效率为（CR＋PR）39．5％；B组有47例：CR14．9％，PR61．7％，总有效率为（CR＋PR）76．6％。结论B组有效率明显高于A组，P〈0．05，疾病无进展时间（PFS）显著延长。因此，FOLFOX4-AVASTIN生物化疗可以作为转移性结直肠癌的一线化疗方案。 |
| 关 键 词： | 结直肠癌 转移性 化疗 FOLFOX4 FOLFOX4-Avastin |
Effect of bevacizumab combined with FOLFOX4 on advanced colorectal cancer |
|
| Affiliation: | XIE Jian-ming,XIE Ya-lin, CHEN Jin-zhang,et al.(Cancer Center,Nan-fang Hospital of Nanfang Medical University,Guangzhou 510515,Guangdong,P. R. China) |
| Abstract: | Aim To observe the effect of FOLFOX4 and FOLFOX4-AVASTIN on metastatic colorectal cancer. Method There 128 colorectal cancer cases with ECOG between 0-2 were be divided into group A （81 cases） and B （47 cases） randomly,and treated with FOLFOX4 and FOLFOX4 plus AVASTIN for 6 courses. Results The overall response rate was 39.5% （complete relieve 1.2% ,part relieve 38.3%） in group A and 76.6%（CR14.9% ,PR61.7%）in group B. Conclusions The response rate of group B was higher obviously than that of group A and showing significant differences （P〈0.005）. FOLFOX4-AVASTIN may be recommend as the fimt line regiment for metastatic colorectal cancer. |
| Keywords: | FOLFOX4 FOLFOX4-Avastin |
| 本文献已被 维普 万方数据 等数据库收录！ | |